Velocity Clinical Research begins its European expansion with the acquisition of a German site


Velocity is the first US-based clinical research site company to expand Europebringing its total number of integrated sites to 32. Velocity has a portfolio of contracts to significantly expand its European network of sites by the end of 2022.

Dominique ClavelExecutive Vice President, Europesaid, “The U.S. pharmaceutical sales market could be twice the size of Europe but the latter contributes a similar percentage of patients to global trials each year. For any clinical trial company, developing a presence in the EU is paramount to its success.

“Velocity Clinical Research is breaking new ground for the clinical research industry. Never before has a US site business been scaled to grow in Europe. Where American businesses have previously struggled to navigate the complex regulatory landscape and cultural differences in Europewe understand them.

“This is the first time that search sites have been truly integrated across America and Europewith a common technology stack and a centralized management team, which offers CROs and pharma companies simplified access to international research.”

Velocity sites are fully owned and fully integrated through a centralized infrastructure and common technology infrastructure, enabling superior patient recruitment and consistent, high-quality data delivery. As a result, clinical research organizations and large pharmaceutical companies can benefit from simplified access to international clinical research.

dr. Christine GrigatManaging Director, Clinical Research Hamburgcommented, “Clinical Research Hamburg is known for being a high quality and successful dedicated research site. We are delighted to be the first European site to join the Velocity Group, establishing its physical presence in Germany.”

Rene Martz, co-owner of Clinical Research Hamburg, added, “The fit was perfect. Clinical Research Hamburg’s focus on providing access to patients with high quality research is reflected in Velocity”.

In 2009, dr. Christine Grigat and René Martz became co-owners of Clinical Research Hamburg to significantly increase its reach in terms of patients recruited for phase II-IV research and customers served in biopharma and CROs. By integrating with Velocity Clinical Research, the site will expand therapy areas to include pain management, allergology, smoking cessation and hypertension.

Doctor Paul EvansCEO and President of Velocity, added: “This is just the beginning. Velocity has ambitious plans to establish itself as a global player, driving more clinical research to success. The focus now is on integrating sites rather than affiliation, which allows for greater predictability and more efficient data collection and delivery.”

About Velocity Clinical Research

Velocity Clinical Research, headquartered in Durham, North Carolina, is the leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity supports global drug development primarily by conducting Phase II and Phase III clinical trials. The company has 32 locations worldwide.

We place patient care at the heart of everything we do. With over 35 years of site management experience and over 7,000 studies performed, Velocity has refined its patient recruitment strategies while emphasizing the provision of reliable and timely data. For more information visit our website at

About Clinical Research Hamburg

Clinical Research Hamburg is a research center specializing in phase II, III and IV outpatient research in a wide range of therapeutic areas. dr. Christine Grigat and René Martz have accompanied the site since its creation in 2004. In 2009, they became managing directors and expanded the number of studies and clients with the biopharmaceutical sector and contract research organizations (CRO). The research site recruits several hundred patients each year for studies in areas such as internal medicine, osteology, orthopedics, gynecology, urology, vaccines and dermatology.

Notes to editors:

  • A complete list of Velocity sites is available on its website.
  • Velocity has extensive experience in vaccines, general medicine, neurology, dermatology, endocrinology, gastroenterology and women’s health.

Photo –

SOURCE Velocity Clinical Research


Comments are closed.